A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

NCT02924766 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Niraparib
DRUG: Apalutamide
DRUG: Abiraterone Acetate
DRUG: Prednisone

Sponsor

Janssen Research & Development, LLC